Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eledon Pharmaceuticals Inc
(NQ:
ELDN
)
3.010
+0.020 (+0.67%)
Streaming Delayed Price
Updated: 9:37 AM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,176
Open
3.030
Bid (Size)
3.000 (2)
Ask (Size)
3.090 (2)
Prev. Close
2.990
Today's Range
3.010 - 3.090
52wk Range
1.070 - 3.349
Shares Outstanding
22,506,956
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's After-Market Session
May 17, 2024
Via
Benzinga
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
May 09, 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+60.11%
+60.11%
1 Month
+49.01%
+49.01%
3 Month
+62.70%
+62.70%
6 Month
+159.48%
+159.48%
1 Year
+40.00%
+40.00%
More News
Read More
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
April 22, 2024
Via
Investor Brand Network
Expert Ratings for Eledon Pharma
November 13, 2023
Via
Benzinga
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
May 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
March 21, 2024
Via
Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 21, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
November 29, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
November 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
October 23, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.